AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06527989
Drug: Ceftriaxone 2000 mg
RxNorm normalized name: ceftriaxone 2000 MG
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antibiotic prophylaxis
Trial: NCT06154538
Drug: Cadonilimab
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1/CTLA-4 bi-specific antibody
Trial: NCT06009029
Drug: Zimberelimab (GLS-010)
RxNorm normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimberelimab (GLS-010),240mg d1 iv Q21D
Trial: NCT00050895
Drug: Lopinavir/ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00050895
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05734495
Drug: Pirtobrutinib
RxNorm normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor, tablet taken orally.
Trial: NCT05734495
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor, tablet taken orally.
Trial: NCT05991388
Drug: Odronextamab
RxNorm normalized name: Odronextamab
DrugBank: Odronextamab (DB16684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD20xCD3 bispecific antibody
Trial: NCT05991388
Drug: Loncastuximab tesirine
RxNorm normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CD-19-directed antibody-drug conjugate
Trial: NCT05991388
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Modified R-ICE chemotherapy
Trial: NCT05991388
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Modified R-ICE chemotherapy
Trial: NCT05991388
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modified R-ICE chemotherapy
Trial: NCT05991388
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modified R-ICE chemotherapy
Trial: NCT05991388
Drug: Etoposide Phosphate
RxNorm normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modified R-ICE (Treatment Arm II)
Trial: NCT05991388
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modified R-ICE chemotherapy
Trial: NCT06048536
Drug: MR-130A-01 Transdermal patch
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MR-130A-01 transdermal patch, containing 2.43 mg Norelgestromin, will be worn 28 days per cycle with no patch free period.
Trial: NCT06048536
Drug: MR-130A-01 Transdermal patch
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MR-130A-01 transdermal patch, containing 3.64 mg Norelgestromin, will be worn 28 days per cycle with no patch free period.
Trial: NCT06048536
Drug: MR-130A-01 Transdermal patch
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 28 days per cycle with no patch free period
Trial: NCT06048536
Drug: MR-130A-01 Transdermal patch
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MR-130A-01 Transdermal patch MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 21 days with a 7-day patch free period.
Trial: NCT05054036
Drug: MoviPrep
RxNorm normalized name: MoviPrep
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Split-dose MoviPrep bowel preparation
Trial: NCT05054036
Drug: Golytely
RxNorm normalized name: GoLYTELY
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Split-dose GoLYTELY bowel preparation
Trial: NCT06252220
Drug: DA-1726
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active
Trial: NCT05752305
Drug: Dexamethasone 4 Mg/mL Injectable Solution
RxNorm normalized name: dexAMETHasone 4 mg/mL injectable solution
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preoperative submucosal administration of 8mg of dexamethasone or 40mg of methylprednisolone.
Trial: NCT06226454
Drug: VX-993
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension for oral administration.
Trial: NCT05152563
Drug: AK002
RxNorm normalized name: MONOCLONAL ANTIBODY AK002
DrugBank: Lirentelimab (DB16728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8
Trial: NCT05858736
Drug: AI-061
RxNorm normalized name: AI-128
DrugBank: AI-128 (DB05841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC- 392 (Anti-CTLA-4) Antibodies.
Trial: NCT00336154
Drug: tetracyclin
RxNorm normalized name: Tetracyclin
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06141486
Drug: Frexalimab
RxNorm normalized name: Frexalimab
DrugBank: Frexalimab (DB18926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR441344 Solution for IV infusion
Trial: NCT06556264
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dupilumab 300mg every 2 weeks for 24 weeks
Trial: NCT04486833
Drug: osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Osimertinib is a 3rd generation EGFR tyrosine kinase inhibitor (TKI) oral tablet administered daily, as indicated for treatment of patients with metastatic NSCLC whose tumors have EGFR genetic deletions or mutations.
Trial: NCT04486833
Drug: Platinum-Based Chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and carboplatin are intravenously administered platinum agents that are combined with other cytotoxic chemotherapy agents such as pemetrexed.
Trial: NCT06016855
Drug: Lutetium Lu 177 Dotatate
RxNorm normalized name: Lutetium Lu 177 dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT06016855
Drug: Copper Cu 64 Dotatate
RxNorm normalized name: copper Cu 64 dotatate
DrugBank: Copper (DB09130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT06275360
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Carboplatin, paclitaxel, and nivolumab for three cycles (for squamous cell lung cancer) or Carboplatin, pemetrexed, and nivolumab for three cycles (for lung adenocarcinoma) Followed by radiotherapy (60 Gy in 30 fractions) Followed by adjuvant nivolumab (six cycles)
Trial: NCT05651022
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab is a PD-1 inhibitor.
Trial: NCT06044311
Drug: Vactosertib
RxNorm normalized name: Vactosertib
DrugBank: Vactosertib (DB15310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg orally, twice daily for five days a week, for 2 weeks and again for 4 weeks after chemoradiotherapy.
Trial: NCT05611268
Drug: Pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Pentoxifylline 400 mg/day for 30 days, followed by 800 mg/day for 150 days
Trial: NCT04712006
Drug: JNJ-64304500
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered with JNJ-64304500 SC (Dose 1 or 2) injection on Day 1.
Trial: NCT05079854
Drug: Moxifloxacin Ophthalmic
RxNorm normalized name: Moxifloxacin Ophthalmic
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Moxifloxacin 0.5%
Trial: NCT05252520
Drug: JNJ-77474462
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-77474462 will be administered subcutaneously.
Trial: NCT05544513
Drug: Ferrous sulfate 3 days week
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive one ferrous sulfate capsule (120 mg of elemental iron) on Mondays, Wednesdays and Fridays
Trial: NCT05544513
Drug: Ferrous sulfate daily
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive one ferrous sulfate (120 mg of elemental iron) capsule daily (except on Sundays)
Trial: NCT05544513
Drug: Ferrous sulfate higher concentration
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive one ferrous sulfate capsule (240mg of elemental iron) on Mondays, Wednesdays and fridays
Trial: NCT06484192
Drug: OxyCODONE 5 mg Oral Tablet
RxNorm normalized name: oxyCODONE 5 mg oral tablet
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: participants will receive OxyCODONE (5 mg) to take for 7 days after surgery as needed
Trial: NCT06484192
Drug: Metaxalone 800 MG
RxNorm normalized name: metaxalone 800 MG
DrugBank: Metaxalone (DB00660)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: participants will receive Metaxalone (800 MG) to take for 7 days after surgery as needed
Trial: NCT04916925
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adding vitamin D to PCOS patients who are resistant to clomiphene regime for induction will or not improve the Clinical pregnancy rate and will or not increase chances of ovulation and pregnancy.
Trial: NCT04916925
Drug: Clomid
RxNorm normalized name: Clomid
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CLOMID is adrug used for ovulation induction
Trial: NCT06544551
Drug: Peginterferon Alfacon-2
RxNorm normalized name: peginterferon alfacon-2
DrugBank: Peginterferon Alfacon-2 (DB19335)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon Alfacon-2 injection will be weekly subcutaneous injected for 48 weeks. Tenofovir alafenamide Fumarate Tablets(TAF) will be take orally for at least 48 weeks, not more than 72 weeks. Peg-interferon Alfacon-2 and TAF will discontinue when HBsAg levels is less than 0.05 IU/mL and HBV DNA is below 10 IU/mL during 48-72 weeks.
Trial: NCT06544551
Drug: Peginterferon Alfacon-2 placebo
RxNorm normalized name: peginterferon alfacon-2
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon Alfacon-2 placebo injection will be weekly subcutaneous injected for 48 weeks. Tenofovir alafenamide Fumarate Tablets(TAF) will be take orally for at least 48 weeks, not more than 72 weeks. Peg-interferon Alfacon-2 and TAF will discontinue when HBsAg levels is less than 0.05 IU/mL and HBV DNA is below 10 IU/mL during 48-72 weeks.
Trial: NCT05996874
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive Dose 1 oral semaglutide D for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days.
Trial: NCT06080789
Drug: RABI-767
RxNorm normalized name: rabies virus
DrugBank: Rabies virus inactivated antigen, B (DB10062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg single-dose given by endoscopic-ultrasound (EUS) guided peripancreatic injection.
Trial: NCT00001095
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001095
Drug: Amprenavir
RxNorm normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00001095
Drug: Nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001095
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00001095
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001095
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06102915
Drug: Rocuronium Bromide 10 MG/ML
RxNorm normalized name: rocuronium bromide 10 MG/ML
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparative
Trial: NCT05958277
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vit B12 upto 250 mcg per day
Trial: NCT05030246
Drug: Surufatinib/Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle.
Trial: NCT05355610
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intratympanic gentamicin and dexamethasone administered in two doses one week apart
Trial: NCT04670055
Drug: BCMA Targeted CAR T-cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject receive BCMA Targeted CAR T-cells by intravenous infusion
Trial: NCT05645692
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive 1200 mg IV atezolizumab Q3W.
Trial: NCT05645692
Drug: Tobemstomig
RxNorm normalized name: Tobemstomig
DrugBank: Tobemstomig (DB18987)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 600 mg IV tobemstomig Q3W.
Trial: NCT05645692
Drug: Tiragolumab
RxNorm normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 600 mg IV tiragolumab Q3W.
Trial: NCT05362058
Drug: Insulin Efsitora Alfa
RxNorm normalized name: Insulin efsitora alfa
DrugBank: Insulin efsitora alfa (DB19013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05362058
Drug: Insulin Degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC
Trial: NCT04571229
Drug: L-MTP-PE
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-MTP-PE will be administered at a dose of 2mg/m2 (maximum dose 4 mg), twice weekly for 12 weeks and weekly for an additional 24 weeks, for a total of 48 doses in 36 weeks.
Trial: NCT00000819
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05389046
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram
Trial: NCT05389046
Drug: Escitalopram+Aripiprazole
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram+Aripiprazole
Trial: NCT05389046
Drug: Escitalopram+omega-3 PUFAs
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram+omega-3 PUFAs
Trial: NCT05389046
Drug: Escitalopram+Aripiprazole+omega-3 PUFAs
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram+Aripiprazole+omega-3 PUFAs
Trial: NCT05794399
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intervention Group:~The patients in the intervention group will be treated with Rivaroxaban 20 mg once daily with the evening meal in patients with a CrCl \>50 mL/min OR 15 mg in cases of moderate-to-severe renal impairment dose with the dosing of once daily with the evening meal in patients with a CrCl ≤50 mL/min. The patient in the intervention group will be requested for follow-up after 3 months of commencing the treatment or whenever the signs and symptoms of bleeding events are noted.
Trial: NCT05794399
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control Group:~The patients in the control group will be treated with Warfarin. The dose will be started with 5 mg and will be titrated based on the International Normalized Ratio (INR) which will be targeted at the range of 2.0 to 3.0. The dual antiplatelet duration will be based on the latest guidelines. The patients will be asked for frequent INR monitoring on an OPD basis until the INR is within the therapeutic range, after which patients will be asked for monthly follow-up INR reports. The patients in the control group will not be treated with heparin or low molecular weight heparin before the INR is maintained in the therapeutic range.
Trial: NCT05024760
Drug: Chlorhexidine
RxNorm normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine will be inserted into the dental implant internal cavity during dental implant insertion.
Trial: NCT05024760
Drug: Hydrogen Peroxide
RxNorm normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrogen Peroxide will be inserted into the internal cavity of the dental implant during dental implant insertion.
Trial: NCT05199493
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients with Delta-renin \>= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with the investigational drug.
Trial: NCT05199493
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with Delta-renin \>= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with placebo
Trial: NCT05285644
Drug: AR 15512 Ophthalmic Solution
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular administration of one drop in both eyes BID for 90 days.
Trial: NCT05635071
Drug: Nintedanib 100 MG [Ofev]
RxNorm normalized name: nintedanib 100 MG [Ofev]
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nintedanib 100mg bid \*15 days orally after hysteroscopic surgery
Trial: NCT05635071
Drug: Nintedanib 150 MG [Ofev]
RxNorm normalized name: nintedanib 150 MG [Ofev]
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nintedanib 150mg bid \*15 days orally after hysteroscopic surgery
Trial: NCT06556472
Drug: Terlipressin
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Patients in this group will receive continuous terlipressin infusion (1 mg/24 hr on day 1, increasing to 1 mg in 24 hours if target MAP not achieved ,reaching maximum terlipressin dose of 4 mg/24 hr on day 4).If target MAP not achieved by terlipressin dose ,increase noradrenaline dose keeping terlipressin maximum 1 mg ,2 mg ,3mg ,4mg at Day 1,2,3,4 respectively.
Trial: NCT06556472
Drug: Norephrine
RxNorm normalized name: Norephedrine
DrugBank: Phenylpropanolamine (DB00397)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Patients in this group will receive norepinephrine only, with a dose range of 0.05 mcg/kg/min to 0.5 mcg/kg/min to maintain a MAP \> 65 to 75 mm Hg.
Trial: NCT05248620
Drug: Amoxicillin Clavulanic 500/125mg or placebo
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotic treatment
Trial: NCT05635851
Drug: Glyceryl Trinitrate Only Product in Oromucosal Dose Form
RxNorm normalized name: Glyceryl trinitrate only product in oromucosal dose form
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate will be administered via sublingual spray.
Trial: NCT04871282
Drug: AL102
RxNorm normalized name: Alpelisib
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AL102 is an inhibitor of gamma secretase-mediated Notch signaling.
Trial: NCT06547528
Drug: ONO-4685
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO-4685 is administered by IV infusion. The administration of ONO-4685 will be continued until disease progression or unacceptable toxicity is observed.
Trial: NCT03929211
Drug: CPI-613
RxNorm normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously, CPI-613 dose will be 2,000 mg/m² and will not escalate.
Trial: NCT03929211
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by mouth, hydroxychloroquine will be dose escalated from 600 mg to 1,200 mg orally given 2 hours before the CPI-613 infusion on days 1-5 of every 28 day cycle in a 3+3 dose escalation design.